Stem cell transplant for RUNX1-related blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is for people with a specific genetic change (RUNX1 mutation) that increases the risk of blood cancers. It tests whether a stem cell transplant from a half-matched family member can help treat or cure these blood conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed change in the RUNX1 gene (a mutation) that is linked to blood cancers, as shown by a genetic test.
- You must have a type of blood cancer or pre-cancer, such as acute or chronic leukemia, myelodysplastic syndrome (MDS), or related conditions. If your disease is more advanced, you may still be able to join after receiving standard treatment to control it.
- You need a family member who is a 'half-match' donor (like a parent, child, or sibling) for the stem cell transplant.
- You must be between 4 and 70 years old.
- You must be able to care for yourself (or have a caregiver) and be willing to stay near the hospital (within a 30-minute drive) for at least 100 days after the transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
This trial tests a special type of stem cell transplant that may help people with certain blood cancers or bone marrow diseases. The transplant uses donor stem cells that are specially selected to reduce the risk of complications. It might be an option for patients who need a transplant to treat their condition.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.